Phase I–II Evaluation of Weekly Mitomycin-C (NSC-26980) for Patients with Metastatic GI and Breast Malignancies

Publisher Website
Google Scholar
Abstract
The experience of Mitomycin-C given as a once weekly intraveneous injection for carcinoma of gastroenteric and breast origin with review of recent literature is given. Limited activity was seen in gastric and colorectal carcinoma. Similar to the experience of others, hematological toxicity (thrombocytopenia and/or leukopenia) was the dose-limiting toxicity encountered. Although the once weekly schedule was not directly compared with other reported schedules, it seems clear there was no reduction of significant and dose-limiting hematological toxicity nor enhancement of therapeutic efficacy.

This publication has 0 references indexed in Scilit: